Can Comparative Effectiveness Study Tell Us What Is The Best Therapy For Class IV Heart Failure? Beta blockers or LVADs?

Slides:



Advertisements
Similar presentations
Advance Heart Failure Therapy
Advertisements

Diuretic Strategies in Patients with Acute Decompensated Heart Failure Diuretic Optimization Strategies Evaluation (DOSE) trial.
Hemolysis in Patients Supported with Durable, Long-Term Left Ventricular Assist Device Therapy Jason N. Katz, MD,MHS; Brian C. Jensen, MD; Patricia P.
Estimating Benefit in Ambulatory Heart Failure Patients MedaMACS Progress Report 2014 Garrick C. Stewart, MD Brigham and Women’s Hospital.
Equipoise Does Not Exist for REVIVE IT Andrew Boyle, MD Heart and Vascular Center Director, Florida Chairman of Cardiology Medical Director of Heart Failure,
Predicting Major Outcomes after MCSD Implant 1 Risk Factors for Death, Transplant, and Recovery James Kirklin, MD David Naftel, PhD.
Preliminary results from the C-Pulse OPTIONS HF European Multicenter Post-Market Study Holger Hotz, CardioCentrum Berlin, Berlin, Germany; Antonia Schulz,
Left Ventricular Assist Devices: The What and the Who Lance E. Sullenberger MD FACC FACP Capital Cardiology Associates.
Ventricular Assist Devices Brian Schwartz, CCP February 25, 2003.
Rejection Normal response Inflammation 25% of pt. will have acute rejection during the first year post transplant Causes: Previous Rejection Noncompliance.
What have we learned? What is next? Panel B: Functional Capacity, Quality of Life and Outcomes H.Functional Capacity I.Neurocognitive Assessment J.Quality.
Introduction to Ventricular Assist Device (VAD)
Coordinator Training Session: March 11, 2012 Major Changes in Data EntryMyers 1 What is the same? What is reduced/removed? What is added/expanded? INTERMACS.
JONATHAN MANT, MD; ABDALLAH AL-MOHAMMAD, MD; SHARON SWAIN, BA, PHD; AND PHILIPPE LARAMEE,DC,MSC, FOR THE GUIDELINE DEVELOPMENT GROUP CHRIS FONTIMAYOR MS-III.
Heart Failure Ben Starnes MD FACC Interventional Cardiology
Heart Failure: From Failure to Success
9/5/20151 Ventricular Assist Device (VAD) Patients in the Community Liz Amerman, RN, BSN IU Health Methodist VAD Program Manager April 18, 2012.
Primary Aim To compare outcomes of participants with symptoms of stable angina or angina equivalent evaluated with an anatomic imaging strategy using CCTA.
Keith Aaronson, Mark Slaughter, Edwin McGee, William Cotts, Michael Acker, Mariell Jessup, Igor Gregoric, Pranav Loyalka, Valluvan Jeevanandam, Allen Anderson,
Ventricular Assist Device: An Advanced Surgical Intervention for the Treatment of End Stage Heart Failure Laura Coyle, MSN, ACNP-BC VAD Coordinator Advocate.
Predicting Patients at Risk for Poor Global Outcomes after DT- MCS Therapy Suzanne V. Arnold, MD, MHA Saint Luke’s Mid America Heart Institute/UMKC May.
Periportal Fibrosis Without Cirrhosis Does Not Affect Outcomes Following Continuous Flow Ventricular Assist Device Implantation Jonathon E. Sargent, BS,
Current Management of Heart Failure GP clinical update 17 th June 2015 Dr Raj Bilku Consultant Cardiologist Clinical Lead Cardiology QEH.
Presentations: Quantifying the impact of adverse events on HRQOL early after implant Patient selection and estimation of prognosis using health status.
Predicting Major Outcomes after MCSD Implant 1 Risk Factors for Death, Transplant, and Recovery James Kirklin, MD David Naftel, PhD.
Value of Endothelin Receptor Inhibition with Tezosentan in Acute Heart Failure Studies VERITAS Trial Presented at The American College of Cardiology Scientific.
Josef Stehlik, MD, MPH Associate Professor of Medicine Medical Director, Heart Transplant Program University of Utah School of Medicine Director, ISHLT.
Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients Assessment.
HeartWare HVAD: Risk Factors for Adverse Outcomes Mark S. Slaughter, MD Professor and Chair Department Cardiovascular and Thoracic Surgery University of.
Medical Progress: Heart Failure. Primary Targets of Treatment in Heart Failure. Treatment options for patients with heart failure affect the pathophysiological.
MCS in Special Populations: The Use of Mechanical Support in Adults with Congenital Heart Disease 9 th Annual Meeting May 15, 2015 Christina VanderPluym,MD.
Survival following VAD complications: implications for transplant priority. Todd Dardas, MD, MS May 16, 2015.
QUEST FOR ULTIMATE CURE “MODEL T” to “DREAM THERAPY” Where is the MIRACLE BULLET? Chittoor B. Sai Sudhakar, MD, FRCS.
Development of a novel predictive model for mortality post continuous flow LVAD implant using Bayesian Networks (BN) N. A. Loghmanpour 1, M. K. Kanwar.
INTERMACS: June 2006 – December 2012: CMS Report Adults: n=7849 All primary implants as of 12/31/2012 n= 7928 Pediatric patients: n=79 (patients < 19 yrs.
TREATMENT OF HEART FAILURE From Oral Medications to Intravenous Drips Mark Puhlman MSN ANP.
“Rise of the Machines” Todd D. Edwards MD FACC FACP FASNC.
Advanced Therapies Lee R. Goldberg, MD, MPH Medical Director, Heart Failure and Cardiac Transplant Program University of Pennsylvania.
Mechanical Circulatory Support in Special Populations Renzo Y. Loyaga-Rendon MD.,PhD.. Assistant Professor Advanced Heart Failure Section University of.
Analysis of Pump Thrombosis in the Intermacs Database Michael Acker William Measey Professor of Surgery Chief of Division of Cardiovascular Surgery Director.
Natural History of Heart Failure
New 2011 SHIFT quality of life substudy Quality of life ( QoL) in heart failure: where do we stand? Therapies that have survival benefits either have a.
1 Data Quality Report Quality Assurance Report Live Data Download Site Datasets (SAS) Research Datasets Customized Cohort Reports Outcome Analytics Patient.
Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Risk Assessment and Comparative Effectiveness of.
Date of download: 6/24/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Year in Cardiovascular Surgery J Am Coll Cardiol.
Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Results of the Destination Therapy Post-Food and.
  Aldosterone Targeted NeuroHormonal CombinEd with Natriuresis TherApy – Heart Failure Trial ATHENA-HF Trial Javed Butler, M.D., M.P.H, M.B.A. On behalf.
Everolimus-eluting Bioresorbable Vascular Scaffolds in Patients with Coronary Artery Disease: ABSORB III Trial 2-Year Results Stephen G. Ellis, MD,
Nephrology Journal Club The SPRINT Trial Parker Gregg
BLOCK HF Study Biventricular versus Right Ventricular Pacing in Patients with Left Ventricular Dysfunction and Atrioventricular Block – Preliminary Results.
David M Kaye MD, PhD on behalf of the REDUCE LAP HF Investigators
Total Artificial Heart (TAH): Survival Outcomes, Risk Factors,
James K. Kirklin, MD, Francis D. Pagani, MD, PhD, Robert L
INTERMACS 10th Annual Meeting March , 2016 Quality of Life
Jennifer A. Cowger, MD, Matthew A
Assist Devices for the Treatment of Cardiogenic Shock
Intermacs and the Scientific Registry of Transplant Recipients (SRTR)
Mechanical circulatory support
Αντιμετώπιση καρδιακής ανεπάρκειας προχωρημένου και τελικού σταδίου
Fifth INTERMACS annual report: Risk factor analysis from more than 6,000 mechanical circulatory support patients  James K. Kirklin, MD, David C. Naftel,
More Than Survival: Futility
INTERMACS So, with more detailed analyses from databases such as CTRD and ISHLT, there is an opportunity for identifying pts who, with their.
G. Michael Felker et al. JCHF 2014;2:
Long-term mechanical circulatory support (destination therapy): On track to compete with heart transplantation?  James K. Kirklin, MD, David C. Naftel,
Cost-effectiveness of left ventricular assist devices (LVADs) for patients with advanced heart failure: Analysis of the British NHS bridge to transplant.
Durability of left ventricular assist devices: Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) 2006 to 2011  William L.
Jacqueline Baras Shreibati et al. JCHF 2017;j.jchf
Optimal timing of cardiac transplantation after ventricular assist device implantation  James S Gammie, MD, Leah B Edwards, PhD, Bartley P Griffith, MD,
Alignment of Comparative Effectiveness through MedaMACS
Presentation transcript:

Can Comparative Effectiveness Study Tell Us What Is The Best Therapy For Class IV Heart Failure? Beta blockers or LVADs?

85% 18 mo 40% 18 mo

Triage Guided By INTERMACS Profiles Importance of comparing a fruit to a fruit Shifting away from Profile 1 over time Device before Transplant vs Direct Transplant without Device vs Device Only Evolution of INTERMACS Profiles INTERMACS patients compared to MedaMACS –Line up by disease severity –Line up by intent Transplant eligibility Likelihood of RV failure? Patient preferences?

REMATCH “Class IV” l 19 unstable on > 2 inotropic agents l 8 patients on 2 agents, couldn’t wean first agent l 3 patients unsuccessful switch of one agent for another l 34 unsuccessful wean due to hypotension or increased dyspnea l 27 met VO2 < 12 criterion on inotropic therapy and did not attempt wean l 38 patients oral therapy only met PkVO2 criteria

% Pts6 Mo Surv Proportion Crash and burn 46% 0.71 Sliding fast40% 0.74 Stable on inotropes 8% 0.88 Resting symptoms home on oral therapy 6% 0.77 All VADS Pagani at al ISHLT 2008 INTERMACS Profiles and VAD Survival

Months post implant % Survival Level 1: n=1391 Deaths=381 Level 2: n=3601 Deaths=942 Level 3: n=2591 Deaths=544 Levels 4-7, n=1789 Deaths=405 P <.0001 Event: Death (censored at transplant and recovery) Figure 10 7 Continuous Flow LVAD/BiVAD Implants: 2008 – 2013, n=9372

We do need a mechanical option before transplantation For INTERMACS 1 and 2 AVERAGE WAIT TIME FOR URGENT PATIENTS = 5 days!

PROFILE-LEVELOfficial Shorthand% Profiles In Bridge INTERMACS LEVEL 1 “Crash and burn” 18% INTERMACS LEVEL 2 “Sliding fast” on ino 42% INTERMACS LEVEL 3 Stable but Ino- Dependent Can be hosp or home 23% INTERMACS LEVEL 4 Resting symptoms on oral therapy at home. 12% INTERMACS LEVEL 5 “ Housebound ”, Comfortable at rest, symptoms with minimum activity ADL 3% INTERMACS LEVEL 6 “Walking wounded”- ADL possible but meaningful activity limited 2% INTERMACS LEVEL 7 Advanced Class III Profile 4 Oral Rx home Profile 5 Profile 6 Profile 7 How many surgeries do Profile 3-4 pts really need? Tx after VAD Is better Tx alone better Patients need support to survive and thrive for transplant. When and what intervention is for housebound or walking wounded?

Dead 12% Alive (device in place) 50% Transplanted 37% Recovery 1% 10 Figure 6 Decreasing eligibility for listed pts after VAD

Triage Guided By INTERMACS Profiles Importance of comparing a fruit to a fruit Shifting away from Profile 1 over time Device before Transplant vs Direct Transplant without Device vs Device Only Evolution of INTERMACS Profiles MedaMACS compared to INTERMACS patients –Line up by disease severity –Line up by intent Transplant eligibility Likelihood of RV failure? Patient preferences?

Intermacs Profile Levels Evolve Cardiac Filling Pressures Over Time Central Venous Pressure No change in Cardiac Index: Every level Both eras Mean 2.1 PA Systolic Pressure Every level Both eras Mean about 50 mm Slight change in PCW Both eras: Level 1= 26, Level 2= 25 Level 3-4 = 24 previous = 23, 22 mm now

Intermacs and MedaMACS Cardiac Filling Pressures Over Time Central Venous Pressure

Intermacs and MedaMACS Systolic Blood Pressure at Implant

Intermacs and MedaMACS Serum Creatinine Levels

Intermacs and MedaMACS Natriuretic Peptide Levels BNP Levels (Similar for NT Pro BNP

Intermacs and MedaMACS Albumin Levels

Triage Guided By INTERMACS Profiles Importance of comparing a fruit to a fruit Evolution of INTERMACS Profiles Device before Transplant vs Direct Transplant without Device vs Device Only MedaMACS compared to INTERMACS patients –Line up by disease severity –Line up by intent Transplant eligibility Likelihood of RV failure? Patient preferences?

What Is Likelihood that MedaMACS Patient Would Need BiVAD if VAD?

What Is Likelihood that MedaMACS Patient Would Be Transplant-Eligible?

Profiles for Comparison Limits of Adjustment

EQ-5D VAS Pre-Implant3 month6 month Months Post Implant Best Worst EQ5D Visual Analog Scale (VAS) across time (± SE) Figure Continuous Flow LVAD/BiVAD implants: 2008 – 2013, n= month18 month24 month Implant Eras P values < ? MedaMACS More or less benefit? ?

INTERMACS and MedaMACS Are Not Two Arms of a Study That requires REMATCH REVIVE IT

Triage Guided By INTERMACS Profiles Importance of comparing a fruit to a fruit Evolution of INTERMACS Profiles Triage for transplant and devices MedaMACS compared to INTERMACS patients –Line up by disease severity –Line up by intent Transplant eligibility Likelihood of RV failure? Patient preferences? We cannot ever say what would have happened with different therapy: –Our answers will be in the form of “ These patients had these outcomes”